Loading
Adding pembrolizumab to carboplatin-paclitaxel and continuing it as maintenance cut the risk of progression by 70 percent in mismatch repair-deficient endometrial cancer and by 46 percent in mismatch repair-proficient disease.
Phase 3 placebo-controlled trial of 816 patients with measurable stage III to IVA, stage IVB or recurrent endometrial cancer randomised to pembrolizumab or placebo with carboplatin-paclitaxel followed by up to 14 maintenance cycles, analysed separately by mismatch repair status.
In mismatch repair-deficient disease, 12-month progression-free survival was 74 versus 38 percent (hazard ratio 0.30); in proficient disease median progression-free survival was 13.1 versus 8.7 months (hazard ratio 0.54).
Together with RUBY, this trial made chemo-immunotherapy the first-line standard for advanced endometrial cancer in both molecular groups, with the largest effect in mismatch repair-deficient tumours.
Shares Mismatch-repair-deficient endometrial cancer, Advanced or recurrent endometrial cancer, Pembrolizumab.
Shares Endometrial cancer with no specific molecular profile, Mismatch-repair-deficient endometrial cancer.
Shares Advanced or recurrent endometrial cancer, New England Journal of Medicine, Pembrolizumab.
Shares Endometrial cancer with no specific molecular profile, Mismatch-repair-deficient endometrial cancer, Advanced or recurrent endometrial cancer, Pembrolizumab.
Shares Mismatch-repair-deficient endometrial cancer, Advanced or recurrent endometrial cancer.
Shares Endometrial cancer with no specific molecular profile, Advanced or recurrent endometrial cancer.
Shares Mismatch-repair-deficient endometrial cancer, Advanced or recurrent endometrial cancer, Pembrolizumab.
Shares Mismatch-repair-deficient endometrial cancer, Pembrolizumab.